ADC Therapeutics Stock

adctherapeutics.comHealthcare / BioTech & PharmaFunding to Date: $200.02MM

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Register To Buy and Sell Shares

For more details on financing and valuation for ADC Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access ADC Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like ADC Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

Susan Romanus
Chief Compliance Officer
Stéphane Henchoz
Director, Finance
David Ellis Ph.D
Head of Global Regulatory Affairs
Patrick Van Berkel Ph.D
Senior Vice President, Research & Development
Michael Forer
Vice Chairman, Executive Vice President & Chief Financial Officer
Maria Cincotta
Head of Global Clinical Science and Operations
Jay Feingold Ph.D
Chief Medical Officer, Senior Vice President Head of Oncology Clinical Development
Richard Warburg Ph.D
Head, Intellectual Property
Chris Martin Ph.D
Chief Executive Officer & Board Member
Michael Mulkerrin Ph.D
Head of Chemistry Manufacturing and Control & Vice President
Esohe Idusogie Ph.D
Head of Process Quality and CMC Analytical
Richard Onyett
Vice President, Business Development

Board Members

Chris Martin Ph.D
Jacques Theurillat
Peter Corr Ph.D
Auven Therapeutics
Thomas Pfisterer
Wild Family Office
Barrie Ward Ph.D
Stephen Evans-Freke
Auven Therapeutics
Tyrell Rivers Ph.D
Peter Hug Ph.D
Thomas Rinderknecht Ph.D

Frequently Asked Questions About ADC Therapeutics’ Stock

Can you buy ADC Therapeutics’ stock?
ADC Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy ADC Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell ADC Therapeutics’ stock?
Yes, you can sell stock of a private company like ADC Therapeutics. Forge can help you sell your ADC Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is ADC Therapeutics’ stock price?
ADC Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access ADC Therapeutics’ private market stock price with Forge Data.
What is ADC Therapeutics’ stock ticker symbol?
ADC Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Updated on: May 18, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.